Regulation - Pricing, Politics

Filter

Current filters:

PricingPolitics

Popular Filters

US lawmakers question price of Gilead’s Sovaldi

US lawmakers question price of Gilead’s Sovaldi

24-03-2014

Three leading US Congressmen have written to John Martin, chief executive of US biotech firm Gilead Sciences,…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPoliticsPricingRegulationSovaldiUSA

Support for the Australia's PBS from Coalition Senators

22-08-2013

Ahead of the September 7 elections, Australian Coalition Senators have issued a statement acknowledging…

Asia-PacificPharmaceuticalPoliticsPricingRegulation

EU Pharma leaders call for right balance between health care budget and economic growth objectives

10-06-2013

The Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA),…

EuropeFinancialPharmaceuticalPoliticsPricingRegulation

Ahead of 2013 federal election, trade group makes plea for fixing Australia's PBS listing system

27-05-2013

Pharma trade group Medicines Australia today (May 27) launched its 2013 Federal Election document, calling…

Asia-PacificHealthcarePatentsPharmaceuticalPoliticsPricingRegulation

Russian government may stop foreign drugmakers from state tendering

10-01-2013

The Russian government is considering imposing a ban on the participation of foreign drug producers in…

EuropePharmaceuticalPoliticsPricingProductionRegulation

EMIG calls for greater clarity on value-based medicines from UK Parliamentary inquiry into NICE

31-10-2012

The UK Ethical Medicines Industry Group (EMIG) has welcomed the House of Commons Health Select Committee's…

BiotechnologyEuropePharmaceuticalPoliticsPricingRegulation

German model for assessment of new medicines slammed by EU pharma leaders

11-06-2012

Leading pharmaceutical companies in Europe, represented in the European Federation of Pharmaceutical…

BiotechnologyEuropePharmaceuticalPoliticsPricingRegulation

Biopharmaceuticals "no longer a growth market" in Germany

30-04-2012

After years of consistent growth, the German biopharmaceuticals market came to a juddering halt last…

BiotechnologyEuropeMarkets & MarketingPharmaceuticalPoliticsPricingRegulation

Canadian patients wait two and a half years for new drug access

09-04-2012

As a result of government bureaucracies to approve new prescription drugs for public use, Canadians are…

North AmericaPharmaceuticalPoliticsPricingRegulation

Back to top